Metabolic syndrome in psychiatry: Advances in understanding and management

Advances in Psychiatric Treatment

Volumn 20, Issue 2, 2014, Pages 101-112

  Ho, Cyrus S H ^a   Zhang, Melvyn W B ^b   Mak, Anselm ^a   Ho, Roger C M ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL HEALTHCARE GROUP   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMANTADINE; AMFEBUTAMONE PLUS NALTREXONE; AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CLOZAPINE; DEXAMPHETAMINE; DEXFENFLURAMINE; DOXEPIN; FAMOTIDINE; FLUOXETINE; LITHIUM; METFORMIN; NIZATIDINE; OLANZAPINE; QUETIAPINE; REBOXETINE; RISPERIDONE; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

ARTICLE; BARIATRIC SURGERY; BINGE EATING DISORDER; BIPOLAR DISORDER; BORDERLINE STATE; CHRONIC INFLAMMATION; DEMENTIA; HEREDITY; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; MENTAL DISEASE; METABOLIC SYNDROME X; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREVALENCE; PSYCHIATRIST; PSYCHOEDUCATION; SCHIZOPHRENIA; SCREENING; SELF HELP; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84896768402     PISSN: 13555146     EISSN: 14721481     Source Type: Journal    
DOI: 10.1192/apt.bp.113.011619     Document Type: Article

References (78)

1. Alberti KG, Eckel RH, Grundy SM, et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120: 1640-5.
2. Anagnostis P, Athyros VG, Tziomalos K, et al (2009) Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. Journal of Clinical Endocrinology & Metabolism, 94: 2692-701.
3. Attvall S, Fowelin J, Lager I, et al (1993) Smoking induces insulin resistance: a potential link with the insulin resistance syndrome. Journal of Internal Medicine, 233: 327-32. (Pubitemid 23114981)
4. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine, 16: 442-3.
5. Bench CJ, Friston KJ, Brown RG, et al (1992) The anatomy of melancholia: focal abnormalities of cerebral blood flow in major depression. Psychological Medicine, 22: 607-15.
6. Bjomtorp P, Rosmond R (2000) The metabolic syndrome - a neuroendocrine disorder? British Journal of Nutrition, 83 (suppl 1): S49-57.
7. Blackburn GL, Hutter MM, Harvey AM, et al (2009) Expert panel on weight loss surgery: executive report update. Obesity (Silver Spring), 17: 842-62.
8. Bloomgarden ZT (2004) Definitions of the insulin resistance syndrome. The 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care, 27: 824-30.
9. Capuron L, Su S, Miller AH, et al (2008) Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biological Psychiatry, 64: 896-900.
10. Chang HH, Chou CH, Chen PS, et al (2009) High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. Journal of Affective Disorders, 117: 124-9.
11. Cheng C, Chiu HJ, Loh EW, et al (2012) Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 36: 205-10.
12. Chi MH, Chang hH, Tzeng NS, et al (2013) The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention. Journal of Affective Disorders, 146: 79-83.
13. Chokka P, Tancer M, Yeragani VK (2006) Metabolic syndrome: relevance to antidepressant treatment. Journal of Psychiatry Neuroscience, 31: 414.
14. Christoph U, Correll MD, Anne M, et al (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second generation antipsychotic drugs. Journal of Clinical Psychiatry, 67: 575-83.
15. Connolly M, Kelly C (2005) Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment, 11: 125-32. (Pubitemid 40331280)
16. Correll CU, Frederickson AM, Kane JM, et al (2007) Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia Research, 89: 91-100. (Pubitemid 44881290)
17. de Hert M, Dekker JM, Wood D, et al (2009) Cardiovascular disease and diabetes in people with severe mental illnesses: position statement from the European Psychiatric Association (EPA), supported by the European Association for the study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry, 24: 412-24.
18. de la Torre JC (2010) The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegenerative Diseases, 7: 116-21.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285: 2486-97.
20. Fagiolini A, Frank E, Scott JA, et al (2005) Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Centre for Pennsylvanians. Bipolar Disorder, 7: 424-30. (Pubitemid 41419409)
21. Fernandez-Egea E, Bernardo M, Parellada E, et al (2008a) Glucose abnormalities in the siblings of people with schizophrenia. Schizophrenia Research, 103: 110-3.
22. Fernandez-Egea E, Miller B, Bernardo M, et al (2008b) Parental history of type 2 disbetes in patients with nonaffective psychosis. Schizophrenia Research, 98: 302-6. (Pubitemid 350245597)
23. Fernandez-Egea E, Miller B, Garcia-Rizo C, et al (2011) Metabolic effects of olanzapine in patients with newly diagnosed psychosis. Journal of Clinical Psychopharmacology, 31: 154-9.
24. Fleischhacker WW, Heikkinen ME, Olie JP, et al (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology, 13: 1115-25.
25. Gebhardt S, Theisen FM, Haberhausen M, et al (2010) Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. Journal of Clinical Pharmacy and Therapeutics, 35: 207-11.
26. Goeb JL, Marco S, Duhamel A, et al (2010) Metabolic side effects of risperidone in early onset schizophrenia (Abstract) [Article in French]. Encephale, 36: 242-52.
27. Grundy SM, Brewer Jr HB, Cleeman JL, et al (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arteriosclerosis, Thrombosis, and Vascular Biology, 24: e13-8.
28. Gurnell M (2001) Endocrinology: Medical Masterclass. Royal College of Physicians.
29. Hansen T, Ingason A, Djurovic S, et al (2011) At risk variant in TCF7L2 for type 2 diabetes increases risk of schizophrenia. Biological Psychiatry, 70: 59-63.
30. Heppner PS, Lohr JB, Kash TP, e al (2012) Metabolic syndrome: relative risk associated with post-traumatic stress disorder (PTSD) severity and antipsychotic medication use. Psychosomatics, 53: 550-8.
31. Holt R, Abdelrahman T, Hirsch M, et al (2010) The prevalence of undiagnosed metabolic abnormalities in people with serious mental illnesses. Journal of Psychopharmacology, 24: 867-73.
32. Hope S, Melle I, Aukrust P, et al (2009) Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disorder, 11: 726-34.
33. Howren MB, Lamkin DM, Suls J (2009) Associations of depression with C-reactive protein, IL-1 and IL-6: a meta-analysis. Psychosomatic Medicine, 71: 171-86.
34. International Diabetes Federation (2006) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. IDF.
35. Kahl KG, Bens S, Ziegler K, et al (2006) Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biological Psychiatry, 59: 667-71. (Pubitemid 43357963)
36. Kahl KG, Greggersen W, Schweiger U, et al (2013) Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. European Archives of Psychiatry and Clinical Neuroscience, 263: 205-13.
37. Kassi E, Pervanidou P, Kaltsas G, et al (2011) Metabolic syndrome: definition and controversies. BMC Medicine, 9: 48.
38. Kim YK, Jung HG, Myint AM, et al (2007) Imbalance between proinflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders, 104: 91-5.
39. Kim MK, Kim SH, Yu HS, et al (2012) The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex. International Journal of Neuropsychopharmacology, 15: 907-17.
40. Koivistoinen T, Hutri-Kahonen N, Juonala M, et al (2009) Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey. Atherosclerosis, 204: 276-81.
41. Koponen HJ, Hakko HH, Saari KM, et at (2010) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World Journal of Biological Psychiatry, 11: 262-7.
42. Kral JG, Buckley MC, Kissileff HR, et al (2001) Metabolic correlates of eating behaviour in severe obesity. International journal of obesity and related metabolic disorders, 25: 258-64.
43. Lee DH, Blomhoff R, Jacobs DR Jr (2004) Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radical Research, 38: 535-9. (Pubitemid 38697087)
44. Lee NY, Kim SH, Cho B, et al (2010) Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population. Progress in Neuropsychopharmacology and Biological Psychiatry, 34: 1243-9.
45. Lee AK, Bishop JR (2011) Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics, 12: 999-1016.
46. Maayan L, Vakhrusheva J, Correll C (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology, 35: 1520-30.
47. McElroy SL, Guerdjikova AI, Martens B, et al (2009) Role of antiepileptic drugs in the management of eating disorders. CNS Drugs, 23: 139-56.
48. McEvoy JP, Meyer JM, Goff DC, et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80: 9-18. (Pubitemid 41587459)
49. McLaughlin T, Abbasi F, Lamendola C, et al (2002) Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation, 106: 2908-12. (Pubitemid 35424740)
50. McIntyre RS, Woldeyohannes HO, Soczynska JK, et al (2010) The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Advances in Therapy, 27: 828-36.
51. McIntyre RS, Alsuwaidan M, Goldstein BI, et al (2012) The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Annals of Clinical Psychiatry, 24: 69-81.
52. Musselman DL, Evans DL, Nemeroff CB (1998) The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Archives of General Psychiatry, 55: 580-92. (Pubitemid 28340345)
53. Na KS, Kim WH, Jung HY, et al (2012) Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 39: 295-300.
54. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. American Journal of Medicine, 124 (1 suppl): S3-18.
55. Newcomer JW (2007) Metabolic syndrome and mental illness. American Journal of Managed Care, 13 (suppl 7): S170-7.
56. Oh JH, Kim TH, Sohn YW, et al (2011) Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and non-alcoholic fatty liver disease. Korean Journal of Hepatology, 17: 27-36.
57. Papanastasiou E (2012) Interventions for the metabolic syndrome in schizophrenia: a review. Therapeutic Advances in Endocrinology and Metabolism, 3: 141-62.
58. Park SH, Kim BI, Yun JW, et al (2004) Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. Journal of Gastroenterology and Hepatology, 19: 694-8. (Pubitemid 38858204)
59. Paslakis G, Gilles M, Lederbogen F, et al (2011) The effect of a 4 week treatment with reboxetine on metabolic parameters of depressed inpatients. European Archives of Psychiatry and Neurological Sciences, 261: 173-7.
60. Patel SB, Reams GP, Spear RM, et al (2008) Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Current Hypertension Reports, 10: 131-7.
61. Potenza MV, Mechanick JI (2009) The metabolic syndrome: definition, global impact, and pathophysiology. Nutrition in Clinical Practice, 24: 560-77.
62. Praharaj SK, Jana AK, Goyal N, et al (2011) Metformin for olanzapineinduced weight gain: a systematic review and meta-analysis. British Journal of Clinical Pharmacology, 71: 377-82.
63. Purnell JQ, Kahn SE, Samuels MH, et al (2009) Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. American Journal of Physiology, Endocrinology and Metabolism, 296: E351-7.
64. Reynolds GP, Templeman LA, Zhang ZJ (2005) The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 29: 1021-8. (Pubitemid 41080129)
65. Roberts RO, Geda YE, Knopman DS, et al (2010) Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Disease and Associated Disorders, 24: 11-8.
66. Ruzickova M, Slaney C, Garnham J, et al (2003) Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Canadian Journal of Psychiatry, 48: 458-61. (Pubitemid 37295203)
67. Saddichha S, Manjunatha N, Ameen S, et al (2008) Metabolic syndrome in first episode schizophrenia: a randomized double-blind controlled, short term perspective study. Schizophrenia Research, 101: 266-72.
68. Skilton MR, Moulin P, Terra JL, et al (2007) Associations between anxiety, depression, and the metabolic syndrome. Biological Psychiatry, 62: 1251-7. (Pubitemid 350060887)
69. Sutherland JP, McKinley B, Eckel RH (2004) The metabolic syndrome and inflammation. Metabolic Syndrome and Related Disorders, 2: 82-104. (Pubitemid 39545406)
70. Takeuchi T, Nakao M, Nomura K, et al (2009) Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study. Diabetes/Metabolism Research and Reviews, 25: 762-7.
71. Taylor AE, Hubbard J, Anderson EJ (1999) Impact of binge eating on metabolic and leptin dynamics in normal young women. Journal of Clinical Endocrinology & Metabolism, 84: 428-34. (Pubitemid 29075664)
72. Une K, Takei YA, Tomita N, et al (2011) Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. European Journal of Neurology, 18: 1006-9.
73. van Himbergen TM, Beiser AS, Ai M, et al (2012) Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Archives of Neurology, 69: 594-600.
74. Vuksan-Cusa B, Sagud M, Jakovljevic M, et al (2012) Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nordic Journal of Psychiatry, PMID: 23228159 [epub ahead of print].
75. Wojciech J, Szmitkowski M (2007) Effects of ethanol on metabolic syndrome. Polish Archives of Internal Medicine, 117: 306-11.
76. World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organization.
77. Yaffe K, Kanaya A, Lindquist K, et al (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA, 292: 2237-42. (Pubitemid 39473161)
78. Yates KF, Sweat V, Yau PL, et al (2012) Impact of metabolic syndrome on cognition and brain: a selected review of the literature. Arteriosclerosis, Thrombosis, and Vascular Biology, 32: 2060-7.